Art. -Nr.: HY-136310

PIP4K-IN-a131

Name: PIP4K-IN-a131
Brand: MedChemExpress
SKU: HY-136310
Price: 260.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC₅₀s of 1.9 μM and 0.6 μM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.42%
CAS. Nr.: 2055405-95-1
Formel: C₂₀H₁₃N₃
Molecular Weight:295.34

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years

* The compound is unstable in solutions, freshly prepared is recommended.

PIP4K-IN-a131 Chemical Structure

CAS. Nr.: 2055405-95-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 1.9 μM (PIP4K2A), 0.6 μM (PIP4Ks)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	2 μM Compound: 4a; A131	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30015072]
AGS	GI₅₀	1.1 μM Compound: 4a; A131	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 30015072]
ARPE-19	GI₅₀	>10 μM Compound: 4a; A131	Antiproliferative activity against human ARPE19 cells after 72 hrs by MTT assay Antiproliferative activity against human ARPE19 cells after 72 hrs by MTT assay	[PMID: 30015072]
AZ-521 cell line	GI₅₀	2.4 μM Compound: 4a; A131	Antiproliferative activity against human AZ-521 cells after 72 hrs by MTT assay Antiproliferative activity against human AZ-521 cells after 72 hrs by MTT assay	[PMID: 30015072]
BJ	GI₅₀	8.1 μM Compound: 4a; A131	Antiproliferative activity against human BJ cells after 72 hrs by MTT assay Antiproliferative activity against human BJ cells after 72 hrs by MTT assay	[PMID: 30015072]
DLD-1	GI₅₀	1.2 μM Compound: 4a; A131	Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 30015072]
HCT-116	GI₅₀	1.8 μM Compound: 4a; A131	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30015072]
HCT-15	GI₅₀	0.5 μM Compound: 4a; A131	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 30015072]
HeLa	GI₅₀	1.4 μM Compound: 4a; A131	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30015072]
HGC-27	GI₅₀	1.2 μM Compound: 4a; A131	Antiproliferative activity against human HGC27 cells after 72 hrs by MTT assay Antiproliferative activity against human HGC27 cells after 72 hrs by MTT assay	[PMID: 30015072]
HT-29	GI₅₀	0.9 μM Compound: 4a; A131	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 30015072]
Huh-7	GI₅₀	1.2 μM Compound: 4a; A131	Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 72 hrs by MTT assay	[PMID: 30015072]
IM95	GI₅₀	1 μM Compound: 4a; A131	Antiproliferative activity against human IM95 cells after 72 hrs by MTT assay Antiproliferative activity against human IM95 cells after 72 hrs by MTT assay	[PMID: 30015072]
IMR-90	GI₅₀	5.8 μM Compound: 4a; A131	Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay	[PMID: 30015072]
MCF7	GI₅₀	1.2 μM Compound: 4a; A131	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30015072]
MDA-MB-231	GI₅₀	1.1 μM Compound: 4a; A131	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30015072]
MKN-45	GI₅₀	1 μM Compound: 4a; A131	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 30015072]
NUGC-3	GI₅₀	1 μM Compound: 4a; A131	Antiproliferative activity against human NUGC3 cells after 72 hrs by MTT assay Antiproliferative activity against human NUGC3 cells after 72 hrs by MTT assay	[PMID: 30015072]
SCH	GI₅₀	1.7 μM Compound: 4a; A131	Antiproliferative activity against human SCH cells after 72 hrs by MTT assay Antiproliferative activity against human SCH cells after 72 hrs by MTT assay	[PMID: 30015072]
SNU1	GI₅₀	0.9 μM Compound: 4a; A131	Antiproliferative activity against human SNU1 cells after 72 hrs by MTT assay Antiproliferative activity against human SNU1 cells after 72 hrs by MTT assay	[PMID: 30015072]
SNU-16	GI₅₀	1 μM Compound: 4a; A131	Antiproliferative activity against human SNU16 cells after 72 hrs by MTT assay Antiproliferative activity against human SNU16 cells after 72 hrs by MTT assay	[PMID: 30015072]
SNU-449	GI₅₀	2.3 μM Compound: 4a; A131	Antiproliferative activity against human SNU449 cells after 72 hrs by MTT assay Antiproliferative activity against human SNU449 cells after 72 hrs by MTT assay	[PMID: 30015072]
TERT-RPE1	GI₅₀	5.2 μM Compound: 4a; A131	Antiproliferative activity against human hTERT-RPE1 cells after 72 hrs by MTT assay Antiproliferative activity against human hTERT-RPE1 cells after 72 hrs by MTT assay	[PMID: 30015072]
U2OS	GI₅₀	1.5 μM Compound: 4a; A131	Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay	[PMID: 30015072]
WI-38	GI₅₀	3.4 μM Compound: 4a; A131	Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay	[PMID: 30015072]

In Vitro

PIP4K-IN-a131 (0-100 μM; 72 hours) is a potent antiproliferative agent with a clear selectivity toward cancer cells killing^[1].
PIP4K-IN-a131 eliminates cancer cells via a dual-inhibitory mechanism^[1].
PIP4K-IN-a131 causes inhibition of the PI3K/Akt/mTOR pathway only in normal BJ cells, but not in transformed counterparts^[1].
Inhibition of PIP4Ks by PIP4K-IN-a131 arrests normal cells at the G1/S phase of the cell cycle by suppressing the PI3K/Akt/mTOR signaling pathway via transcriptional upregulation of PIK3IP1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Normal and transformed BJ cells
Concentration:

0-100 μM (MTT assay)
Incubation Time:

72 hours
Result:

Selective killed cancer cells.

RT-PCR^[1]

Cell Line:

BJ cells
Concentration:

5 µM
Incubation Time:

24 hours
Result:

Induced the upregulation of PIK3IP1 mRNA levels.

Chemical Information

CAS. Nr. 2055405-95-1
Appearance Solid
Molecular Weight 295.34
Formel C₂₀H₁₃N₃
Color Light yellow to yellow
SMILES

N#C/C(C1=CNC2=C1C=CC=C2)=C\C3=CC=CC4=C3C=CN=C4
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (2)

All

Sort by:

Journal Impact Factor

Nat Commun

PIP4K2B is mechanoresponsive and controls heterochromatin-driven nuclear softening through UHRF1. [Abstract]

2023 Mar 14;14(1):1432. PMID: 36918565
bioRxiv

2025 January 29.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 62.5 mg/mL (211.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3859 mL

16.9296 mL

33.8593 mL

5 mM

0.6772 mL

3.3859 mL

6.7719 mL

10 mM

0.3386 mL

1.6930 mL

3.3859 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (7.04 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (7.04 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Mayumi Kitagawa, et al. Dual Blockade of the Lipid Kinase PIP4Ks and Mitotic Pathways Leads to Cancer-Selective Lethality. Nat Commun. 2017 Dec 19;8(1):2200. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3859 mL	16.9296 mL	33.8593 mL	84.6482 mL
	5 mM	0.6772 mL	3.3859 mL	6.7719 mL	16.9296 mL
	10 mM	0.3386 mL	1.6930 mL	3.3859 mL	8.4648 mL
	15 mM	0.2257 mL	1.1286 mL	2.2573 mL	5.6432 mL
	20 mM	0.1693 mL	0.8465 mL	1.6930 mL	4.2324 mL
	25 mM	0.1354 mL	0.6772 mL	1.3544 mL	3.3859 mL
	30 mM	0.1129 mL	0.5643 mL	1.1286 mL	2.8216 mL
	40 mM	0.0846 mL	0.4232 mL	0.8465 mL	2.1162 mL
	50 mM	0.0677 mL	0.3386 mL	0.6772 mL	1.6930 mL
	60 mM	0.0564 mL	0.2822 mL	0.5643 mL	1.4108 mL
	80 mM	0.0423 mL	0.2116 mL	0.4232 mL	1.0581 mL
	100 mM	0.0339 mL	0.1693 mL	0.3386 mL	0.8465 mL

Bioz

Keywords

PIP4K-IN-a131

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PIP4K-IN-a131

Publications Citing Use of MedChemExpress (MCE) PIP4K-IN-a131